Response to avapritinib by baseline S/A/R status (prior systemic therapy pooled efficacy population)
| Best response . | Prior systemic therapy pooled efficacy population (n = 31) . | |
|---|---|---|
| ≥1 S/A/R mutation(s) at baseline (n = 13) . | No S/A/R mutations at baseline (n = 18) . | |
| ORR, n (%) (95% CI) (CR+CRh+PR+CI) | 8 (62) (32-86) | 14 (78) (52-94) |
| CR, n (%) | 0 | 1 (6) |
| CRh, n (%) | 3 (23) | 2 (11) |
| PR, n (%) | 3 (23) | 11 (61) |
| CI, n (%) | 2 (15) | 0 |
| SD, n (%) | 1 (8) | 3 (17) |
| PD, n (%) | 0 | 1 (6) |
| NE, n (%) | 4 (31) | 0 |
| Best response . | Prior systemic therapy pooled efficacy population (n = 31) . | |
|---|---|---|
| ≥1 S/A/R mutation(s) at baseline (n = 13) . | No S/A/R mutations at baseline (n = 18) . | |
| ORR, n (%) (95% CI) (CR+CRh+PR+CI) | 8 (62) (32-86) | 14 (78) (52-94) |
| CR, n (%) | 0 | 1 (6) |
| CRh, n (%) | 3 (23) | 2 (11) |
| PR, n (%) | 3 (23) | 11 (61) |
| CI, n (%) | 2 (15) | 0 |
| SD, n (%) | 1 (8) | 3 (17) |
| PD, n (%) | 0 | 1 (6) |
| NE, n (%) | 4 (31) | 0 |
Percentages have been rounded to whole numbers and may not add up to 100%.